[8-K] Autolus Therapeutics plc American Depositary Share Reports Material Event

Rhea-AI Filing Summary

Autolus Therapeutics announced it has released its financial results for the quarter ended June 30, 2025 and provided a corporate update. The company furnished a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) that it will use in a conference call; both exhibits are expressly noted as furnished rather than filed.

The 8-K clarifies that the information in the exhibits is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless specifically stated. The form text does not include the underlying financial tables, revenue, expense or cash metrics, so detailed figures and operational commentary must be obtained from the attached Exhibit 99.1 and Exhibit 99.2.

Positive

• Quarterly results and corporate update announced, indicating timely communication of company performance
• Press release (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2) furnished for the conference call, improving investor access to materials

Negative

• The 8-K does not include financial metrics or operational tables; detailed figures are only in the furnished exhibits
• Materials are furnished, not filed, which limits Section 18 liability and means the 8-K text is not incorporated by reference into other filings unless explicitly stated

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished via press release and presentation; 8-K contains no financial line items.

The filing signals that Autolus has released quarterly results and a corporate presentation, which supports transparency around near-term performance. Because the materials are "furnished" and not "filed," the 8-K text itself provides limited analytical value: it confirms the event and points to exhibits for substance. Analysts should review Exhibit 99.1 and 99.2 for revenue, expense, cash position and any management commentary before adjusting models.

Corporate Governance Expert

TL;DR: Standard Regulation FD and results disclosure; furnishing limits Section 18 liability but fulfills disclosure obligations.

From a disclosure controls perspective, the company followed common practice by furnishing the press release and presentation and by stating the exhibits are not incorporated by reference. This protects against certain post-filing liabilities while ensuring investors receive the information. The 8-K lists exhibits clearly but does not itself provide the substantive metrics, so governance and compliance teams have met procedural requirements but stakeholders must access the exhibits for full disclosure.

0001730463FALSE00017304632025-08-122025-08-120001730463sic:Z88802025-08-122025-08-120001730463us-gaap:CommonClassAMember2025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

Autolus Therapeutics plc

(Exact name of registrant as specified in its Charter)

England and Wales			001-38547						Not applicable
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)
The Mediaworks
191 Wood Lane
London						W12 7FP
United Kingdom
(Address of principal executive offices)(Zip Code)
(44) 20						3829 6230
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share			AUTL			The Nasdaq Global Select Market
Ordinary shares, nominal value $0.000042 per share*			*			The Nasdaq Stock Market LLC*

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Conditions.

On August 12, 2025, Autolus Therapeutics plc (the “Company”) announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

In connection with its conference call on August 12, 2025 to discuss its results for the quarter ended June 30, 2025, the Company will utilize an updated corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

d) Exhibits

Exhibit No.						Description of Exhibit
99.1						Press release dated August 12, 2025
99.2						Corporate Presentation dated August 12, 2025
104						Cover Page Interactive Date File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						AUTOLUS THERAPEUTICS PLC
Dated: August 12, 2025			By:			/s/Christian Itin, Ph.D.
						Name: Christian Itin, Ph.D.
						Title: Chief Executive Officer

FAQ

What did Autolus (AUTL) disclose in this 8-K?

The company announced it released financial results for the quarter ended June 30, 2025 and provided a corporate update; a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) were furnished.

Where can I find the full financial results for AUTL?

The full financial figures and operational commentary are contained in the furnished Exhibit 99.1 (press release) and Exhibit 99.2 (corporate presentation); the 8-K text does not include the tables.

Are the exhibits in this AUTL 8-K filed or furnished?

The filing states the press release and presentation are furnished, not filed, and therefore are not subject to Section 18 liabilities and are not incorporated by reference into other filings unless explicitly stated.

Which exhibits were included with the 8-K?

Exhibit 99.1 is the press release, Exhibit 99.2 is the updated corporate presentation, and Exhibit 104 is the Cover Page Interactive Data File.

Does the 8-K provide forward-looking guidance or detailed metrics?

No. The 8-K text does not include forward-looking guidance or detailed financial metrics; those items, if present, would be in the furnished exhibits.